The Effect of Melatonin and Vitamin C on COVID-19

Lancaster General Hospital

Status: Completed

Conditions: SARS-CoV Infection; Covid19

Treatments: Other: Symptom Survey; Dietary Supplement: Placebo; Dietary Supplement: melatonin; Dietary Supplement: Vitamin C

Study type: Interventional

Funder types: Other

Identifiers

NCT04530539

2020-68

Details and patient eligibility

About

This is a double-blind placebo controlled trial that seeks to evaluate the impact of melatonin and vitamin C on symptoms and outcomes of patients with COVID-19.

Enrollment: 122 patients

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• COVID-19 positive test (outpatient testing),
• Age >50 (chosen based greater risk for older patients to be vitamin deficient, age >65 not used so as not to be too restrictive in the inclusion criteria)
• Experiencing symptoms for <5 days prior to enrollment
• Able to read and write in English or Spanish
• Able to access REDCap daily
• Valid email address
• Current has a Lancaster General Health primary care physician

Exclusion Criteria

• COVID-19 test ordered pre-procedure for asymptomatic screening
• Currently taking vitamin C supplements
• Currently taking melatonin supplements
• Currently hospitalized
• Deceased
• Currently pregnant
• Currently incarcerated

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

122 participants in 3 patient groups, including a placebo group

Experimental- Melatonin

Experimental group

Description:

Patients will receive melatonin

Treatment:

Dietary Supplement: melatonin

Other: Symptom Survey

Experimental- Vit C

Experimental group

Description:

Patients will receive vitamin C

Treatment:

Dietary Supplement: Vitamin C

Other: Symptom Survey

Control

Placebo Comparator group

Description:

Patients will receive placebo

Treatment:

Dietary Supplement: Placebo

Other: Symptom Survey